
Hepta Blood Test Surpasses FIB-4, ELF, and FibroScan in Detecting Treatment-Eligible MASH Patients
Hepta’s Blood Test Outperforms FIB-4, ELF, and FibroScan in Identifying Treatment-Eligible MASH Patients Hepta, a liquid biopsy company developing blood tests for chronic disease, announced clinical data showing its blood test more accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) patients eligible…











